Baseline | Week 11 | Week 16 | Week 26 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sample errorless | Sample trial and error | Errorless, | Baseline trial and error, | Errorless, | Trial and error, | Group ∆, | Errorless, | Trial and error, | Group ∆, | Errorless, | Trial and error, | Group ∆, | |
(N) | (N) | mean (SD) | mean (SD) | mean (SD) | mean (SD) | mean (95% CI) | mean (SD) | mean (SD) | mean (95% CI) | mean (SD) | mean (SD) | mean (95% CI) | |
Primary patient-related outcome | |||||||||||||
Task performance rating video A (1 = worst, 7 = best) | 69 | 71 | 3.0 (1.6) | 3.5 (1.5) | 4.3 (1.7) | 4.2 (1.7) | –0.1 (–0.6, 0.5) | 4.4 (1.8) | 4.1 (1.8) | 0.3 (–0.3, 0.9) | 3.8 (1.8) | 4.0 (1.7) | 0.3 (–0.5, 0.8) |
Task performance rating video B (1 = worst, 7 = best) | 69 | 71 | 3.1 (1.6) | 3.9 (1.7) | 4.7 (1.6) | 4.3 (1.6) | –0.4 (–0.9, 0.1) | 4.3 (1.8) | 4.4 (1.6) | –0.1 (–0.5, 0.7) | 4.1 (2.0) | 3.9 (1.9) | –0.2 (–0.9, 0.5) |
Secondary patient-related outcomes | |||||||||||||
IDDD A initiative (0 = worst, 36 = best) | 69 | 71 | 18.4 (6.6) | 18.2 (5.8) | 17.7 (7.0) | 16.8 (7.2) | –0.9 (–3.3, 1.5) | 16.2 (7.5) | 15.7 (7.4) | –0.4 (–3.1, 2.0) | |||
IDDD B performance (44 = worst, 0 = best) | 69 | 71 | 21.3 (6.0) | 21.4 (7.2) | 21.0 (8.6) | 20.9 (9.0) | 0.0 (–3.0, 2.9) | 22.3 (10.2) | 23.6 (10.1) | 1.4 (–2.1, 4.8) | |||
Treatment satisfaction (5 = worst, 1 = best) | 69 | 71 | 1.5 (0.6) | 1.5 (0.5) | 0.0 (–0.2, 0.2) | 1.5 (0.9) | 1.4 (0.7) | –0.1 (–0.4, 0.2) | |||||
Control measures | |||||||||||||
MMSE (0 = worst, 30 = best) | 69 | 71 | 19.8 (3.3) | 19.7 (3.3) | 19.0 (4.8) | 19.6 (4.2) | 0.6 (–0.9, 2.1) | 18.2 (5.2) | 18.9 (5.1) | 0.7 (–1.1, 2.4) | |||
Reisberg Clinical Dementia Rating (1 = worst, 7 = best) | 69 | 71 | 4.3 (0.6) | 4.3 (0.7) | 4.4 (0.6) | 4.4 (0.7) | 0.1 (–0.2, 0.3) | 4.4 (0.6) | 4.4 (1.0) | 0.0 (–0.3, 0.3) | |||
NPIQ (36 = worst, 0 = best) | 69 | 71 | 7.2 (4.0) | 7.5 (5.2) | 7.9 (5.2) | 8.1 (5.2) | –0.1 (–1.7, 1.8) | 8.0 (5.4) | 8.6 (6.5) | 0.6 (–1.5, 2.7) |